Antithrombin alfa clinical trials
Also written ATryn and KW-3357.
How each study uses antithrombin alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 6 Feb 2009 · Atryn · BLA 125284 (FDA, Purple Book)
- European Union
- 28 Jul 2006 · ATryn · EMEA/H/C/000587 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 3
Kyowa Kirin Co., Ltd. (4) · rEVO Biologics (2) · LEO Pharma (1) · Mayo Clinic (1) · Medical College of Wisconsin (1) · Children's Hospital Los Angeles (1)
Studies
Open first, then newest update. How each study uses antithrombin alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe SepsisTerminatedPhase 2LEO PharmaNCT00506519Written as Antithrombin alfa (INN name)
- A Study of KW-3357 in Congenital Antithrombin DeficiencyCompletedPhase 1Kyowa Kirin Co., Ltd.NCT00938288Written as KW-3357
- Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm PreeclampsiaCompletedPhase 3rEVO BiologicsNCT02059135Written as Recombinant human antithrombin (ATryn)
- A Clinical Study of KW-3357 in Patients With DICCompletedPhase 3Kyowa Kirin Co., Ltd.NCT01384396Written as KW-3357
- An Open-label Study of KW-3357CompletedPhase 3Kyowa Kirin Co., Ltd.NCT01384903Written as KW-3357
- A Phase 3 Clinical Study of KW-3357 in Patients With DICTerminatedPhase 3Kyowa Kirin Co., Ltd.NCT01384409Written as KW-3357
- Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac SurgeryTerminatedPhase 4Mayo ClinicNCT01547728Written as Recombinant antithrombin (rhAT)
- Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMOWithdrawnPhase 4Children's Hospital Los AngelesNCT01913444Written as Recombinant Antithrombin
- Antithrombin III Supplementation for Cardiopulmonary Bypass in NeonatesTerminatedPhase 1Medical College of WisconsinNCT01158729Written as Antithrombin (Recombinant)
- Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.CompletedPhase 3rEVO BiologicsNCT00056550Written as Recombinant Human Antithrombin (rhAT)
Given beside what is tested · 1 — antithrombin alfa is usual care or a partner of the new treatment
Codes
What other systems call antithrombin alfa · ClinicalTrials.gg INT016038
- UNII (FDA) AWV6I5L6H2ANTITHROMBIN ALFAConfirmed FDA, Wikidata
- RxNorm 1427179Confirmed FDA, Wikidata
- Wikidata Q28852422antithrombin alfaConfirmed FDA, Wikidata
- NCI Thesaurus C82234Antithrombin AlfaConfirmed FDA, Wikidata
- DrugBank DB11166One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | AWV6I5L6H2 | ANTITHROMBIN ALFA | Confirmed FDA, Wikidata |
| RxNorm | 1427179 | — | Confirmed FDA, Wikidata |
| Wikidata | Q28852422 | antithrombin alfa | Confirmed FDA, Wikidata |
| NCI Thesaurus | C82234 | Antithrombin Alfa | Confirmed FDA, Wikidata |
| DrugBank | DB11166 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.